NEW YORK - Kennesaw-based CryoLife Incorporated shares tumbled as much as 15 percent Tuesday after revealing that its human-tissue processing laboratories received a warning from the Food and Drug Administration. <br>
<br>
Shares of CryoLife were down about ten percent to $21.41 Tuesday afternoon on the New York Stock Exchange. <br>
<br>
CryoLife processes implantable living human tissues for use in cardiovascular, vascular and orthopedic surgeries. <br>
<br>
Late Monday, the company says one inspection occurring in December was sparked by the death of a Minnesota man, who developed an infection after receiving connective tissue from CryoLife during a knee operation. <br>
<br>
The company says tests at CryoLife in December were negative for microorganisms, and the FDA took no action after that event. <br>
<br>
Inspections in March and April followed reports of two heart valve infections. Although the company ultimately determined that there was no evidence of infection in either valve, the FDA nonetheless made inspections and issued a number of recommendations.
